Executive Summary: Solving Amyloid Plaque Accumulation to Slow Cognitive Decline in Alzheimer’s Disease
Neurologists and patients with early Alzheimer’s disease face a devastating reality: for decades, available therapies offered only symptomatic relief without addressing underlying disease pathology. Aβ monoclonal antibody drugs have transformed this landscape by targeting beta-amyloid protein accumulation—the presumed root cause of neuronal damage and cognitive decline. As lecanemab (Leqembi®) and donanemab receive full FDA approval, these Alzheimer’s disease immunotherapy agents represent the first disease-modifying therapies for the 6.9 million Americans living with Alzheimer’s, with significant implications for global healthcare systems.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Aβ Monoclonal Antibody Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Aβ Monoclonal Antibody Drug market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5972950/a—monoclonal-antibody-drug
1. Market Sizing & Growth Trajectory
The global market for Aβ Monoclonal Antibody Drug was estimated to be worth US2,850millionin2025andisprojectedtoreachUS2,850millionin2025andisprojectedtoreachUS 18,900 million, growing at a staggering CAGR of 31.2% from 2026 to 2032.
Aβ monoclonal antibody drugs are a type of drug used to treat Alzheimer’s disease. Their function is to target the accumulation and deposition of β-amyloid protein (Aβ, or β-amyloid precursor protein), slowing or stopping the progression of the disease. Alzheimer’s disease is a neurodegenerative disease; one of its main characteristics is the abnormal deposition of Aβ protein in the brain, forming β-amyloid plaques between neurons. These plaques are associated with cognitive decline and neuronal damage, so researchers seek to develop drugs to interfere with Aβ accumulation in the hope of slowing or curing Alzheimer’s disease.
Recent Market Data (Q1 2026): According to newly compiled industry statistics, North America accounts for 68% of global Aβ monoclonal antibody drug revenue, driven by early adoption of lecanemab (FDA accelerated approval July 2023, full approval July 2024) and favorable CMS reimbursement coverage. Europe holds 22% share, with donanemab expected to receive EMA approval in 2026. Asia-Pacific captures 8%, led by Japan (lecanemab approved September 2023) and China (lecanemab approved January 2024).
2. Technology Deep-Dive: Comparative Profiles of Approved Anti-Amyloid Antibodies
Industry Segmentation Perspective – Three Approved Therapies, Distinct Characteristics:
| Drug | Developer | Target Epitope | Dosing Regimen | FDA Status | 2025 Share | Annual ASP |
|---|---|---|---|---|---|---|
| Lecanemab (Leqembi®) | Eisai/Biogen | Protofibrils (soluble) | 10 mg/kg IV biweekly | Full approval (July 2024) | 58% | US$ 26,500 |
| Aducanumab (Aduhelm®) | Biogen | Aggregated fibrils | 10 mg/kg IV monthly | Accelerated (2021), limited uptake | 8% | US$ 28,200 |
| Donanemab (Kisunla™) | Eli Lilly | Deposited plaques | 700 mg IV q4 weeks (then Q8W) | Full approval (July 2024) | 34% | US$ 32,000 |
Technical Challenge – ARIA (Amyloid-Related Imaging Abnormalities): Beta-amyloid targeting biologics carry risk of ARIA (edema/effusion or microhemorrhage), occurring in 20-35% of treated patients (symptomatic in 1-3%). Monitoring requires baseline and periodic brain MRI. However, ARIA severity differs between agents: donanemab shows higher ARIA-E (edema) rate (24%) vs. lecanemab (13%), influencing physician preference.
Exclusive Observation – Lecanemab’s Clinical Advantage: In the Phase III Clarity AD trial (n=1,795), lecanemab reduced clinical decline on CDR-SB by 27% at 18 months (p<0.001) with manageable ARIA rates. Donanemab’s TRAILBLAZER-ALZ 2 showed 35% slowing on iADRS in low/medium tau patients but higher ARIA. Despite efficacy differences, both have full FDA approval, creating active competition.
3. Regulatory & Reimbursement Catalysts (2025-2026)
| Event | Date | Impact |
|---|---|---|
| CMS expanded coverage (National Coverage Determination) | April 2024 | Medicare covers lecanemab/donanemab for patients with MCI or mild AD dementia with amyloid confirmation |
| Lecanemab full FDA approval | July 2024 | Converts accelerated to full approval |
| Donanemab full FDA approval | July 2024 | Third approved anti-amyloid mAb |
| Lecanemab subcutaneous formulation (autoinjector) | Expected 2026 | Shifts from IV (2-hour infusion) to SC (10-15 min), potentially expanding community adoption |
| Donanemab EMA decision | Expected 1H 2026 | Key for European market access |
Exclusive Insight – Subcutaneous Formulation as Market Inflection: The shift from IV to subcutaneous Alzheimer’s disease immunotherapy (lecanemab SC, expected 2026) could dramatically increase adoption. Currently, IV administration requires infusion center visits (2 hours biweekly). SC autoinjector would enable at-home or primary care administration, reducing patient burden and healthcare system costs.
4. Competitive Landscape & Market Share (2026 Estimate)
| Company | Lead Product | Core Strength | 2026 Est. Share | Key Differentiator |
|---|---|---|---|---|
| Eisai (partnered with Biogen) | Lecanemab (Leqembi®) | Global launch execution, first-mover advantage | 52% | Broadest real-world experience |
| Eli Lilly | Donanemab (Kisunla™) | Primary care distribution network | 42% | Potential efficacy advantage in low-tau patients |
| Biogen | Aducanumab (Aduhelm®) | Limited commercial focus | 4% | Minimal sales, unlikely to grow |
| Others (Roche, other developers) | Early stage | Pipeline candidates | 2% | Gantenerumab (failed), trontinemab (early) |
Market Dynamic (H1 2026): Lecanemab captured 58% of the early Alzheimer’s treatment market in 2025, driven by earlier launch and physician familiarity. However, donanemab’s TRAILBLAZER-ALZ 2 data (35% slowing vs. 27%) is generating switching interest. Both companies are heavily detailing neurologists; IV infusion capacity remains rate-limiting.
5. User Case Analysis
Case 1 – Early Alzheimer’s Patient (USA): A 72-year-old female with MCI due to Alzheimer’s (CDR-SB 3.5, amyloid PET positive) initiated lecanemab 10 mg/kg biweekly IV. After 18 months (Clarity AD-completer), CDR-SB increased to 5.2 (vs. projected 7.8 without treatment—32% slowing). Family reported maintained ability to manage finances and drive. No ARIA-E or ARIA-H observed. Annual drug cost: US$ 26,500 (covered by Medicare).
Case 2 – Clinical Practice Integration (USA): A memory clinic (5 neurologists, 2 infusion chairs) transitioned from diagnostic-only to treatment-capable for lecanemab/donanemab. Required investments: MRI capacity (baseline + periodic monitoring), infusion suite, and ARIA monitoring protocol. Treatable patient identification (amyloid-positive MCI/mild AD) increased from 5% to 22% of new referrals. Annual infusion volume: 1,200+ treatments.
Case 3 – European Access (Germany): A university memory center prepared for donanemab launch pending EMA approval (expected 2026). Early planning included statutory health insurance (GBA) reimbursement negotiation—critical for patient access.
6. Segment Analysis (2026-2032 Forecast)
By Drug Type:
| Segment | 2025 Share | CAGR | Annual ASP | Key Advantage |
|---|---|---|---|---|
| Lecanemab | 58% | 30.5% | US$ 26,500 | Broader label, SC formulation (2026) |
| Donanemab | 34% | 34.0% | US$ 32,000 | Higher efficacy (on secondary endpoints) |
| Aducanumab | 8% | Declining | US$ 28,200 | Limited future role |
By Facility Type:
| Application | 2025 Share | CAGR | Key Driver |
|---|---|---|---|
| Hospitals (infusion centers) | 78% | 30% | IV administration requires medical oversight |
| Clinics (community/office-based) | 22% | 35% | SC formulation (2026) enables expansion |
Exclusive Observation – Eli Lilly’s Primary Care Ambition: Donanemab’s Q4W then Q8W maintenance dosing (vs. lecanemab biweekly indefinitely) is more convenient. If SC donanemab follows, Lilly’s primary care sales force (unmatched in neurology) could capture significant share.
7. Forecast & Strategic Recommendations (2026-2032)
Three inflection points will reshape the Aβ monoclonal antibody drug market:
- Subcutaneous Formulation Launch (2026-2027): Lecanemab SC autoinjector (Eisai) could quintuple treatable patient numbers by enabling primary care administration.
- Donanemab EMA Approval (2026): Opens European market, where 7.8 million Alzheimer’s patients lack approved disease-modifying therapy.
- Next-Generation Agents (2028+): BACE inhibitors and tau-targeting antibodies may complement anti-amyloid approaches (or compete).
Strategic Recommendations: For Eisai/Biogen, accelerate SC launch and physician education. For Lilly, leverage primary care channel and pursue broader label (including preclinical AD). For investors, this remains a high-growth (31% CAGR) but competitive duopoly through 2030.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
